OPTN News and Press, OptiNose Inc. From 07/30/20

YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2020 and corporate updates...

YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currentl...

Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Document Security Systems (NYSEMKT: DSS ) +69%  after its target acquisition Company, Impact Biomedical reports positive results of equivir and linebacker for treatment of COVID-19. More news on: Document Security Systems, Inc., Infinity Pharmaceuticals, Inc., Dolphin Entertainment...

OptiNose (NASDAQ: OPTN ) +22.3% after-hours on news of an agreement with pharmaceutical firm Kaléo to co-promote its XHANCE exhalation nasal spray for the treatment of nasal polyps in adult patients. More news on: OptiNose, Inc., Healthcare stocks news, Stocks on the move, Rea...

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building...

Gainers:  Ayro (NASDAQ: AYRO )  +102% . More news on: Ayro, Inc., Electrameccanica Vehicles Corp., LM Funding America, Inc., Stocks on the move, , Read more ...

Optinose ( OPTN +25.2% ) initiates development of a new product candidate, OPN-019, which will combine the Company’s proprietary nasal Exhalation Delivery System (EDS) technology with an antiseptic that has been recently shown  in vitro  to kill the virus that causes COV...

YARDLEY, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced initiation of development of a new product candidate, OPN-019. OPN-019 will combine the Com...

YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upda...